Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
ASTX-295 by Taiho Pharmaceutical for Malignant Pleural Mesothelioma: Likelihood of Approval
ASTX-295 is under clinical development by Taiho Pharmaceutical and currently in Phase II for Malignant Pleural Mesothelioma. According to GlobalData,...
ASTX-295 by Taiho Pharmaceutical for Glioblastoma Multiforme (GBM): Likelihood of Approval
ASTX-295 is under clinical development by Taiho Pharmaceutical and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData,...
ASTX-295 by Taiho Pharmaceutical for Uveal Melanoma: Likelihood of Approval
ASTX-295 is under clinical development by Taiho Pharmaceutical and currently in Phase II for Uveal Melanoma. According to GlobalData, Phase...
ASTX-295 by Taiho Pharmaceutical for Solid Tumor: Likelihood of Approval
ASTX-295 is under clinical development by Taiho Pharmaceutical and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
ASTX-295 by Taiho Pharmaceutical for Well Differentiated Liposarcoma: Likelihood of Approval
ASTX-295 is under clinical development by Taiho Pharmaceutical and currently in Phase II for Well Differentiated Liposarcoma. According to GlobalData,...